WOODBRIDGE, May 11, 2015 /PRNewswire/ - Pivotal
Therapeutics Inc. (CSE:PVO; OTCQX:PVTTF), ("Pivotal" or the
"Company"), a specialty pharmaceutical company with a focus on
Omega-3 therapies for cardiovascular disease and overall health,
announced today the company and Mrs. Rachelle MacSweeney, Co-Founder, President and
COO will be featured on CEO Clips on CBC's
The Documentary Channel. CEO Clips, a series which profiles
the most innovative publicly traded companies in North America, will feature Pivotal on The
Documentary Channel beginning May 11,
2015, Monday through Friday, throughout the day and
evenings. It can also be viewed online via this link:
http://www.b-tv.com/pivotal-therapeutics-ceo-clip/.
In addition it will be posted on these financial portals: BNN.ca
Finance, Canadian Business Journal, Thomson Reuters Insider
Network, MSN Money , Stockhouse, YouTube, Blinkx, on our stock
symbol page as well as on CEO Clips.
About CBC's The Documentary Channel
"Documentary is a digital television station devoted to
showing the best documentaries from Canada and around the world. With its special
emphasis on feature length films, watching Documentary is like
having a cinema in your own living room, showing award winning
films twenty-four hours a day, seven days a week."
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded (CSE:PVO;
OTCQX:PVTTF), specialty pharmaceutical company with a focus on
cardiovascular disease and overall health. Pivotal Therapeutics'
lead product VASCAZEN® is a prescription only
medical food formulated to meet the dietary Omega-3 deficient needs
of patients with cardiovascular disease through elevating
Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular
complications. OMAZEN® is a pharmaceutical grade
Omega-3 providing over 90% pure Omega-3 in each capsule for the
maintenance of good health. OMAZEN® is a patented
product available for sale and distribution in Canada for the professional market.
BeneFishial™ is the first product in Pivotal's new
nutraceutical product line, which has been specifically designed to
be sold in the OTC direct to retail or direct to consumer
markets.
Disclosure Notice
The information contained in this
document is as May 11, 2015. This
press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual
results to differ materially from those projected in such
forward-looking statements. These statements can be identified by
the use of words such as "will", "anticipate", "estimate",
"expect", "project", "forecast", "intend", "plan", "believe",
"project", "potential", and similar expressions with any discussion
of future operating or financial performance or events. In
particular, factors that could cause actual results to differ
materially from those in forward looking statements include the
following: Pivotal's inability to obtain additional financing on
acceptable terms; growth in costs and expenses; inability to
compete with others who provide comparable products; risk that the
Company's products will not gain widespread market acceptance;
risks relating to the Company's ability to maintain its CSE
listing. Forward-looking statements speak only as of the date made
and are not guarantees of future performance. The Company
undertakes no obligation to publicly update or revise any
forward-looking statements contained in this document as a result
of new information or future events or developments. The CSE has
not reviewed and does not accept responsibility for the adequacy or
accuracy of this information.
SOURCE Pivotal Therapeutics Inc.
